All donations go towards web site maintenance for all of Technical Watch,
keep it free of charge, and may be tax deductable as an investment expense.


PayPal Verified
Join our market chat sessions every Tuesday and Thursday at 4:00 pm Pacific time!
More information on subscriber services can be found at
http://www.technicalwatch.com/subs.htm




Support Technical Watch!
Buy from our Book Store!
Register Calendar Latest Topics
 
 
 


Reply
  Author   Comment  
biohit

TW Member
Registered:
Posts: 8
Reply with quote  #1 

http://www.investtech.com/main/market.php?CompanyID=35100236

 

This means that there is a huge market of people who could benefit from cysteine – around 0.5 billion people worldwide.

The global market potential for GastroPanel, BioCyst and XyliCyst combined is estimated to be as much as €5bn.

http://www.nutraingredients.com/news/ng.asp?id=67991-biohit-oyj-cysteine-xylicyst-biocyst

0
biohit

TW Member
Registered:
Posts: 8
Reply with quote  #2 

05.01.2007 16:20
BIOHIT'S INNOVATIVE GASTROPANEL TO BE USED IN CHINA'S HEALTH CARE
 
http://www.biohit.com/view/products.asp?document_id=914&cat_id=914

0
biohit

TW Member
Registered:
Posts: 8
Reply with quote  #3 
BIOHIT PLANS TO INCORPORATE ITS DIAGNOSTICS BUSINESS BIOHIT OYJ STOCK EXCHANGE RELEASE 26 JANUARY 2007 BIOHIT PLANS TO INCORPORATE ITS DIAGNOSTICS BUSINESS At a meeting held on Friday 26 January 2007, Biohit Oyj’s Board of Directors decided to investigate the possibility of hiving off the company’s diagnostics business into a separate limited company. The purpose is also to obtain its own equity in order to boost international marketing and distribution and thereby rapidly and effectively leverage the significant potential of existing and forthcoming products. The decision forms part of the company’s new strategy, which aims to clarify the differences and synergies between its business areas and derive the full benefit from their strengths, as well as to boost the Group’s business as a whole and improve earnings. Biohit Oyj currently operates in two business segments: the liquid handling business and the diagnostics business. The company’s liquid handling business develops, manufactures and markets laboratory equipment and supplies for use in the pharmaceutical, food and other industries, as well as for use in research institutions, universities and hospitals, and to complement the diagnostic and analysis systems of many other companies, such as 3M, bioMérieux and three Johnson&Johnson Group companies. Biohit’s diagnostics business primarily develops, manufactures and markets products and analysis systems for diagnosing, screening for and preventing gastrointestinal diseases. The product range includes Biohit’s patented GastroPanel examination – a test that from a blood sample diagnoses diseases of the gastric mucosa and their associated risks (see, for example, http://www.gastropanel.net, http://www.biohit.com / Diagnostics). Biohit’s business segments differ in, for example, their market situations and customer bases, distribution channels and marketing, and production processes. When the diagnostics business is hived off into a separate company, both businesses will be better able to focus on developing their own strengths. When established, the new company will focus primarily on developing, manufacturing and marketing diagnostics tests and analyses systems for diagnosing, screening for and preventing diseases of the digestive tract. It will also develop, manufacture and market products for eliminating carcinogenic substances (see http://www.biohit.com / Investors / Stock Exchange Releases: 5 January 2007). Biohit Oyj Board of Directors
0
biohit

TW Member
Registered:
Posts: 8
Reply with quote  #4 

FINANCIAL STATEMENT REPORT OF BIOHIT GROUP 1 JAN TO 31 DEC 2006
BIOHIT OYJ   STOCK EXCHANGE RELEASE   16 FEB 2007   10:00 AM  

 

http://www.biohit.com/view/products.asp?document_id=914&cat_id=914

0
biohit

TW Member
Registered:
Posts: 8
Reply with quote  #5 
http://www.investtech.com/main/market.php?CompanyID=35100236

29.05.2007 15:11
Biohit Oyj Company Announcement BIOHIT AND VWR INTERNATIONAL SIGN AGREEMENT FOR DISTRIBUTION IN EUROPE
Biohit Oyj and VWR International, a leading global distributor of scientific    
equipment, supplies, chemicals and furniture, have entered into an agreement
concerning sales and marketing of liquid handling products in Europe. The new
agreement further strengthens Biohit's distribution network in Europe, one of
its major market areas, and the company's position in key market segments. The
agreement comes into effect immediately.

0
biohit

TW Member
Registered:
Posts: 8
Reply with quote  #6 
http://www.traderit.net/forum/forum_entry.php?id=14693
0
Previous Topic | Next Topic
Print
Reply

Quick Navigation:

Easily create a Forum Website with Website Toolbox.






Copyright 2000-2017 Technical Watch